PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

BACKGROUND: The optimal duration of immune checkpoint blockade (ICB) in lung cancer remains undefined. Indefinite treatment in long-term responders increases health care burden, exposes patients to avoidable toxicities, and is not supported by any clinical or biological rationale or translational data. Prospective strategies to determine the optimal duration of immunotherapy in lung cancer are urgently needed. PATIENTS AND METHODS: In this retrospective cohort study, 455 patients from 21 National Network Genomic Medicine Lung Cancer Germany (nNGM) centers with

• Frost, N.
• Joosten, M.
• Franzen, J.
• Wiesweg, M.
• Rasokat, A.
• Kulhavy, J.
• Kollmeier, J.
• Reinmuth, N.
• Grohé, C.
• Roeper, J.
• Rittmeyer, A.
• Heinzen, S.
• Wermke, M.
• Wesseler, C.
• Christopoulos, P.
• Kauffmann-Guerrero, D.
• Althoff, A.
• Bleckmann, A.
• Collienne, M.
• Berezucki, E.
• Overbeck, T.
• Kropf-Sanchen, C.
• Griesinger, F.
• Sebastian, M.
• Schuler, M.
• Braun, S.
• Wenzel, C.
• Furth, C.
• Wolf, J.
• Bischoff, P.
• Reck, M.